These findings highlight the interplay between IL‐6, GDF‐15, sarcopenia and tumour progression, suggesting that IL‐6 and GDF‐15 may serve as valuable prognostic biomarkers and potential therapeutic targets. Here, IL6 is linked to sarcopenia.